- 7 McGonigal G, McQuade C, Thomas B and Whalley LJ. Survival in presenile Alzheimer's and multi-infarct dementias. *Neuroepidemiology* 1992;11:121-6.
- 8 Martin GM, Schellenberg GD, Wijsman EM, Bird TD. Dominant susceptibility genes. *Nature* 1990;347:124.
- 9 Morris JN. *Uses of epidemiology*. Edinburgh: Livingstone, 1964.
- 10 World Health Organisation. *International Classification of Disease*. Fifth edition. Geneva: WHO, 1977.
- 11 Cohen J. A coefficient of agreement for nominal scales. *Education and Psychological Measures* 1960;20:37-46.
- 12 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease; report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 1984;34:939-44.
- 13 Hachinski VC, Illiff LD, Zalka E, duBoulay GHD, McAlister VL, Marshall J, et al. Cerebral blood flow in dementia. *Arch Neurol* 1975;32:632-7.
- 14 McGonigal G, Thomas B, McQuade C, Whalley LJ. Clinical diagnosis of presenile Alzheimer's disease: a novel approach. *International Journal of Geriatric Psychiatry* 1992;7:751-6.
- 15 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 16 Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby M, Hughes J. Interrater reliability of Alzheimer's disease diagnosis. *Neurology* 1990;40:257-61.
- 17 Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender and education. *Ann Neurol* 1990;27:428-37.
- 18 Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. *Acta Psychiatr Scand* 1987;76:465-79.
- 19 Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. *Am J Epidemiol* 1987;125:420-36.
- 20 Rocca WA, Bonaiuto S, Lippi A, Luciano P, Turtu F, Cavarzeran F, et al. Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: a door-to-door survey in Appignano, Macerata Province, Italy. *Neurology* 1990;40:626-31.
- 21 Buhl L, Bojsen-Moller M. Frequency of Alzheimer's disease in a postmortem study of psychiatric patients. *Dan Med Bull* 1988;35:288-90.

(Accepted 31 December 1992)

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

Fujian Song, Nick Freemantle, Trevor A Sheldon, Allan House, Paul Watson, Andrew Long, James Mason

Abstract

Objective—To examine the evidence for using selective serotonin reuptake inhibitors instead of tricyclic antidepressants in the first line treatment of depression.

Design—Meta-analysis of 63 randomised controlled trials comparing the efficacy and acceptability of selective serotonin reuptake inhibitors with those of tricyclic and related antidepressants.

Main outcome measures—Improvement in mean scores on Hamilton depression rating scale for 53 randomised controlled trials. Pooled drop out rates from the 58 trials which reported drop out by treatment group.

Results—Among the 20 studies reporting standard deviation for the Hamilton score no difference was found in efficacy between serotonin reuptake inhibitors and tricyclic and related antidepressants (standardised mean difference 0.004, 95% confidence interval -0.096 to 0.105). The difference remained insignificant when the remaining 33 studies that used the 17 item and 21 item Hamilton score were included by ascribing weighted standard deviations. The odds ratio for drop out rate in patients receiving serotonin reuptake inhibitors compared with those receiving tricyclic antidepressants was 0.95 (0.86 to 1.07). Similar proportions in both groups cited lack of efficacy as the reason for dropping out but slightly more patients in the tricyclic group cited side effects (18.8% v 15.4% in serotonin reuptake group).

Conclusions—Routine use of selective serotonin reuptake inhibitors as the first line treatment of depressive illness may greatly increase cost with only questionable benefit.

Introduction

Selective serotonin reuptake inhibitors are a relatively new class of antidepressants that have been heavily promoted for use as first line treatment in depression. They are the most commonly prescribed antidepressant in the United States,¹ but their routine use in Britain is controversial.^{2,4}

The high specificity of serotonin reuptake inhibitors, without antagonism of neurotransmitter receptors or direct cardiac effects, has led to the expectation that they have the same antidepressant activity as tricyclic

and related antidepressants but do not produce many of the common side effects.⁵ Thus it is claimed that they have two important advantages over tricyclic and related antidepressants—they are better tolerated and are less toxic in overdose.⁴ However, disagreement exists about the role of serotonin reuptake inhibitors in treating major depression.^{2,3}

One reason for these differences of opinion is that the claims made for serotonin reuptake inhibitors are often based on the results of individual trials.² Many of the studies are not large enough to detect or exclude with certainty clinically relevant differences in the effects of serotonin reuptake inhibitors and tricyclic and related drugs. We reviewed the evidence for the efficacy and acceptability of serotonin reuptake inhibitors compared with the tricyclic and related antidepressants by meta-analysis. We included data from all comparable randomised controlled trials, which enables smaller effects to be detected or excluded with confidence. The large number of studies also gives the findings potentially greater generalisability.

Methods

We conducted a meta-analysis of the results of efficacy studies and of the drop out rates. We identified 64 randomised controlled trials comparing serotonin reuptake inhibitors with tricyclic or related antidepressants by searching Medline and *Index Medicus*, manual cross referencing, and discussion with experts (table 1).⁶⁻⁹ One study did not use a double-blind design and was therefore excluded from the analysis.¹¹ Some multicentre studies have been published in aggregate and separately, and we took great care to avoid including the same results more than once.⁷⁰

EFFICACY

The trials used various psychometric instruments to measure the efficacy of treatments. The most consistently used instrument, the Hamilton depression rating scale,^{71,72} was included in 61 of the trials. The Hamilton depression rating scale is a reliable instrument that is particularly weighted towards and sensitive to change in somatic symptoms rather than psychological and cognitive factors.⁷³ Most studies used either the 17 question or the 21 question instrument, although other versions were occasionally used. However, it is generally accepted that none of the items which supplement

School of Public Health,
University of Leeds, Leeds
Fujian Song, research fellow
Nick Freemantle, research
fellow

Centre for Health
Economics, University of
York, York YO1 5DD
Trevor A Sheldon, senior
research fellow
James Mason, research fellow

Department of Liaison
Psychiatry, Leeds General
Infirmary, Leeds
Allan House, consultant
psychiatrist

Academic Unit of Public
Health Medicine,
University of Leeds
Paul Watson, senior registrar

Nuffield Institute for
Health Services Studies,
University of Leeds, Leeds
Andrew Long, senior lecturer

Correspondence to:
Mr Sheldon.

BMJ 1993;306:683-7

TABLE 1—Randomised clinical trials on the treatment of major depression with serotonin reuptake inhibitors and tricyclic and related antidepressants

Author (year)	Serotonin reuptake inhibitors (mg/day)	Tricyclic antidepressants (mg/day)	No of weeks' treatment	No of patients		Difference in mean Hamilton score* (SE)	No of drop outs		Odds ratio of drop outs (95% confidence interval)
				Serotonin reuptake inhibitors	Tricyclic antidepressants		Serotonin reuptake inhibitors	Tricyclic antidepressants	
Altamura <i>et al</i> ^a (1989)	Fluoxetine (20)	Amitriptyline (75)	5	14	14	4.00 (2.38)†	2	4	0.42 (0.06 to 2.77)
Amore <i>et al</i> ^a (1989)	Fluvoxamine (50-150)	Imipramine (50-150)	4	15	15	1.00 (NA)‡	0	5	
Bascara ^a (1989)	Paroxetine (20-30)	Amitriptyline (50-75)	6	27	23	NA	2	3	0.53 (0.08 to 3.51)
Bignamini and Rapisarda ^a (1992)	Paroxetine (20-30)	Amitriptyline (75-150)	6	156	153	1.00 (NA)‡	31	20	1.65 (0.89 to 3.04)
Bramanti <i>et al</i> ¹⁰ (1988)	Fluvoxamine (50-150)	Imipramine (50-150)	4	30	30	2.65 (1.21)‡	2	1	2.07 (0.18 to 24.15)
Bremner ¹² (1984)	Fluoxetine (20-80)	Imipramine (75-300)	5	20	20	NA	4	3	1.42 (0.27 to 7.34)
Bressa <i>et al</i> ¹³ (1989)	Fluoxetine (20-60)	Imipramine (50-175)	5	15	15	4.00 (NA)‡	2	1	2.15 (0.17 to 26.67)
Chouinard ¹⁴ (1985)	Fluoxetine (20-80)	Amitriptyline (75-300)	5	25	28	4.80 (NA)‡	4	6	0.70 (0.17 to 2.83)
Cohn and Wilcox ¹⁵ (1985)	Fluoxetine (20-80)	Imipramine (100-300)	6	54	54	-1.15 (NA)‡	19	34	0.32 (0.15 to 0.70)
Cohn <i>et al</i> ¹⁶ (1990)	Sertraline (50-200)	Amitriptyline (50-150)	8	161	80	-0.60 (NA)†	79	41	0.92 (0.54 to 1.57)
Cohn <i>et al</i> ¹⁷ (1990)	Paroxetine (10-50)	Imipramine (65-275)	6	NA	NA	2.00 (NA)†	NA	NA	
Corne and Hall ¹⁸ (1989)	Fluoxetine (40)	Dothiepin (75)	6	49	51	2.20 (1.36)†	14	7	2.51 (0.92 to 6.90)
Danish University anti-depressant group ¹⁹ (1990)	Paroxetine (30)	Clomipramine (150)	6	62	58	6.00 (NA)†	35	23	1.97 (0.95 to 4.08)
Debus <i>et al</i> ²⁰ (1988)	Fluoxetine (20-60)	Trazodone (50-400)	6	22	21	2.00 (NA)†	8	10	0.63 (0.19 to 2.13)
de Jonghe <i>et al</i> ²¹ (1991)	Fluvoxamine (50-300)	Maprotiline (50-150)	6	24	24	-0.10 (2.16)†	4	6	0.60 (0.15 to 2.47)
de Jonghe <i>et al</i> ²² (1991)	Fluoxetine (40-80)	Maprotiline (50-150)	6	30	35	2.60 (2.03)†	4	6	1.19 (0.49 to 2.89)
De Wild <i>et al</i> ²³ (1983)	Fluvoxamine (223-300)	Clomipramine (109-144)	6	21	23	1.30 (NA)†	0	0	
Dick and Ferrero ²⁴ (1983)	Fluvoxamine (150)	Clomipramine (150)	4	17	15	1.80 (NA)§	4	3	1.23 (0.23 to 6.67)
Dominguez <i>et al</i> ²⁵ (1985)	Fluvoxamine (50-300)	Imipramine (50-300)	4	35	35	-0.40 (NA)§	19	16	1.41 (0.55 to 3.61)
Dorman ²⁶ (1992)	Paroxetine (15-30)	Amitriptyline (30-60)	6	29	28	-4.00 (NA)†	5	3	1.74 (0.37 to 8.08)
Dunbar <i>et al</i> ²⁷ (1991)	Paroxetine (20-50)	Imipramine (65-275)	6	240	240	0.00 (NA)†	102	127	0.66 (0.46 to 0.94)
Dunner <i>et al</i> ²⁸ (1992)	Paroxetine (10-40)	Doxepin (<200)	6	136	135	-1.00 (NA)‡	45	39	1.22 (0.73 to 2.04)
Fabre <i>et al</i> ²⁹ (1991)	Fluoxetine (35)	Nortriptyline (87)	5	103	102	0.00 (NA)§	39	45	0.77 (0.44 to 1.35)
Falk <i>et al</i> ³⁰ (1989)	Fluoxetine (20-60)	Trazodone (50-400)	6	14	13	-0.07 (4.25)‡	3	10	0.08 (0.01 to 0.50)
Feighner <i>et al</i> ³¹ (1991)	Fluoxetine (20-80)	Bupropion (225-450)	6	62	61	1.40 (NA)‡	18	16	1.15 (0.52 to 2.54)
Feighner (1989)	Fluvoxamine (85-280)	Imipramine (50-280)	6	31	36	-5.00 (NA)‡	10	9	1.43 (0.49 to 4.15)
Feighner and Cohn ³¹ (1985)	Fluoxetine (20-80)	Doxepin (50-250)	6	78	79	-0.29 (NA)‡	37	48	0.58 (0.31 to 1.10)
Feighner ³² (1985)	Fluoxetine (20-80)	Amitriptyline (75-300)	5	22	22	2.00 (NA)‡	5	12	0.25 (0.06 to 0.90)
Ferreni ³³ (1989)	Fluoxetine (20)	Amitriptyline (100)	6	31	32	-0.30 (NA)‡	4	7	0.53 (0.14 to 2.03)
Ginestet ³⁴ (1989)	Fluoxetine (58)	Clomipramine (148)	8	NA	NA	0.20 (2.67)‡	NA	NA	
Gonella <i>et al</i> ³⁵ (1990)	Fluvoxamine (100-150)	Imipramine (100-150)	4	10	10	-1.90 (3.92)‡	1	0	
Guelfi <i>et al</i> ³⁶ (1987)	Fluvoxamine (100-300)	Imipramine (50-200)	4	77	81	-2.60 (1.86)§	19	18	1.15 (0.55 to 2.40)
Guillibert <i>et al</i> ³⁷ (1989)	Paroxetine (20-30)	Clomipramine (25-75)	6	40	39	0.20 (NA)‡	9	12	0.65 (0.24 to 1.79)
Guy <i>et al</i> ³⁸ (1984)	Fluvoxamine (150-225)	Imipramine (150-225)	6	17	19	NA	NA	NA	
Hutchinson <i>et al</i> ³⁹ (1992)	Paroxetine (20)	Amitriptyline (100)	6	58	32	0.00 (NA)‡	12	11	0.50 (0.19 to 1.31)
Itil <i>et al</i> ⁴⁰ (1983)	Fluvoxamine (50-210)	Imipramine (50-210)	4	22	25	NA	12	12	1.30 (0.41 to 4.10)
Kuhs and Rudolf ⁴¹ (1989)	Paroxetine (30)	Amitriptyline (150)	6	20	20	0.40 (NA)‡	6	3	2.43 (0.51 to 11.51)
Laakmann <i>et al</i> ⁴² (1988)	Fluoxetine (20-60)	Amitriptyline (50-150)	5	65	65	5.00 (2.45)†	29	22	1.57 (0.78 to 3.20)
Lapierre <i>et al</i> ⁴³ (1987)	Fluvoxamine (180)	Imipramine (173)	6	22	21	-5.00 (NA)†	7	12	0.35 (0.10 to 1.22)
Laursen <i>et al</i> ⁴⁴ (1985)	Paroxetine (30)	Amitriptyline (50-150)	6	21	23	2.00 (NA)†	5	9	0.49 (0.13 to 1.80)
Levine <i>et al</i> ⁴⁵ (1987)	Fluoxetine (40-60)	Imipramine (75-150)	6	30	30	3.40 (NA)‡	8	2	5.09 (0.98 to 26.43)
Loeb <i>et al</i> ⁴⁶ (1989)	Fluoxetine (20)	Imipramine (50-75)	5	15	15	-5.76 (NA)‡	NA	NA	
Manna <i>et al</i> ⁴⁷ (1989)	Fluoxetine (20)	Clomipramine (75)	5	15	15	-1.00 (1.65)†	NA	NA	
March <i>et al</i> ⁴⁸ (1990)	Fluvoxamine (50-300)	Imipramine (50-300)	6	18	18	-2.00 (NA)†	5	3	1.92 (0.38 to 9.65)
Mertens and Pintens ⁴⁹ (1988)	Paroxetine (30)	Mianserin (60)	6	38	32	-6.00 (NA)‡	5	4	1.06 (0.26 to 4.34)
Muijen <i>et al</i> ⁵⁰ (1988)	Fluoxetine (40-80)	Mianserin (40-80)	6	26	27	-4.00 (3.38)†	12	13	0.92 (0.31 to 2.72)
Mullin <i>et al</i> ⁵¹ (1988)	Fluvoxamine (100-300)	Dothiepin (75-225)	6	37	36	-0.20 (NA)†	11	12	0.85 (0.32 to 2.27)
Nielsen <i>et al</i> ⁵² (1991)	Paroxetine (20-40)	Imipramine (100-200)	12	16	15	-2.00 (NA)†	4	1	0.52 (0.12 to 2.17)
Norton <i>et al</i> ⁵³ (1984)	Fluvoxamine (133)	Imipramine (153)	4	35	31	0.30 (NA)†	4	1	3.87 (0.41 to 36.66)
Perez and Ashford ⁵⁴ (1990)	Fluvoxamine (100-600)	Mianserin (60-360)	6	30	33	NA	9	9	1.14 (0.38 to 3.41)
Perry <i>et al</i> ⁵⁵ (1989)	Fluoxetine (20-60)	Trazodone (50-400)	6	21	19	1.90 (2.64)§	4	4	0.88 (0.19 to 4.16)
Peselow <i>et al</i> ⁵⁶ (1989)	Paroxetine (10-50)	Imipramine (65-275)	6	40	40	8.56 (NA)†	11	12	0.89 (0.34 to 2.33)
Phanjoo <i>et al</i> ⁵⁷ (1991)	Fluvoxamine (100-200)	Mianserin (40-80)	6	25	25	Did not use	9	10	0.84 (0.27 to 2.65)
Poelinger and Haber ⁵⁸ (1989)	Fluoxetine (40)	Maprotiline (75)	4	73	69	-1.00 (1.13)§	12	8	1.50 (0.57 to 3.93)
Rahman <i>et al</i> ⁵⁹ (1991)	Fluvoxamine (50-200)	Dothiepin (50-200)	6	26	26	Did not use	9	7	1.44 (0.44 to 4.70)
Reimherr <i>et al</i> ⁶⁰ (1990)	Sertraline (50-200)	Amitriptyline (50-150)	8	126	122	1.72 (0.82)†	61	63	0.95 (0.60 to 1.50)
Ropert ⁶¹ (1989)	Fluoxetine (20)	Clomipramine (75)	5	71	72	-1.40 (0.97)‡	16	24	0.58 (0.28 to 1.22)
Roth <i>et al</i> ⁶² (1990)	Fluvoxamine (100-300)	Desipramine (100-300)	6	30	30	-1.20 (2.56)†	6	9	0.58 (0.18 to 1.91)
South Wales Antidepressant Drug Trial Group ⁶³ (1988)	Fluoxetine (40-80)	Dothiepin (50-225)	6	31	28	-0.40 (1.72)†	15	7	2.81 (0.93 to 8.52)
Stark and Hardison ⁶⁴ (1985)	Fluoxetine (20-80)	Imipramine (100-300)	6	185	186	0.30 (1.05)‡	87	87	1.01 (0.67 to 1.52)
Tamminen and Lehtinen ⁶⁵ (1989)	Fluoxetine (40-80)	Doxepin (50-150)	5	26	25	-1.00 (NA)†	5	4	1.25 (0.29 to 5.31)
Taneri and Köhler ⁶⁶ (1989)	Fluoxetine (40)	Nomifensine (150)	5	20	20	-2.50 (2.47)§	5	1	6.33 (0.67 to 60.17)
Young <i>et al</i> ⁶⁷ (1987)	Fluoxetine (40-80)	Amitriptyline (50-150)	6	32	32	NA	7	7	1.00 (0.31 to 3.27)

*The difference in mean Hamilton score was calculated from data reported at the last week of the trial: difference in mean score=mean score in serotonin reuptake inhibitor group—mean score in tricyclic group. †17 Item Hamilton scale. ‡21 Item Hamilton scale. §Other items or unknown items of Hamilton scale. NA=not available.

the basic 17 questions provide additional information of value.

The mean difference in Hamilton scores between patients treated with serotonin reuptake inhibitors and those treated with tricyclic or related antidepressants (treatment difference) was calculated for each trial. A pooled estimate of the treatment difference was calculated by averaging all the treatment differences, weighting each by the inverse of the individual squared standard errors.⁷⁴ This gave larger studies, with tighter confidence intervals, more influence in the pooled estimate of difference in efficacy than smaller ones.

Only 20 trials presented the standard deviation of Hamilton scores needed to calculate the weights. A test for heterogeneity (non-random differences) of standardised treatment difference between the studies, with

a χ^2 statistic, showed no significant heterogeneity ($Q=23.58$, $df=19$; $p=0.213$),⁷⁵ so a fixed effects method was used to estimate the pooled difference in efficacy.⁷⁶

To avoid the potential bias from using only 20 trials, we ascribed a standard deviation to the remaining 33 studies which used the 17 or 21 item Hamilton scale. Since the standard deviations of the scores from the 16 trials using the 17 or 21 item scale were similar, for each scale a weighted average of these standard deviations was used to calculate a standard error for each of the 33 studies. Pooled estimates of treatment differences were calculated for all 49 studies and compared with the estimate derived from the 16 studies that presented standard deviations for either the 17 or 21 item Hamilton scale.

Acceptability to patients is an important element in a treatment's effectiveness.⁷⁷ Drop out, which is a useful measure of acceptability,⁷⁸ was reported in 58 trials. We compared drop out rates in the two arms of the trials and analysed the main subjective reasons given by patients for discontinuing therapy (inefficacy and side effects) when available.

The ratio of drop out rate of patients in the serotonin reuptake inhibitor group to that in the tricyclic and related antidepressant group (odds ratio) was calculated for each study. A pooled estimate of the overall odds ratio of drop out was calculated by weighting each odds ratio by the inverse of the variance; thus studies with more subjects were given more weight. The odds ratio was heterogeneous among studies ($Q=78.79$, $df=57$; $p=0.03$) and so the pooled odds ratio was calculated by a random effects method.^{75 79}

Results

EFFICACY

Of the 20 trials which presented the mean Hamilton score and its standard deviations, six used the 21 item Hamilton scale, 10 the 17 point scale and four other versions. Pooled results are presented separately for the 17 and 21 item version of the scale and then all 20 trials were combined by using the standardised difference between mean Hamilton scores for the serotonin reuptake inhibitor and tricyclic and related antidepressant groups: Standardised difference = difference between means/standard deviation.

The average baseline Hamilton score was about 26 on the 21 item scale and 24 on the 17 item scale. No significant difference was found in mean Hamilton score in the 21 item scale for serotonin reuptake inhibitors compared with tricyclic and related anti-

TABLE II—Drop out rate in patients treated with serotonin reuptake inhibitors and tricyclic and related antidepressants

	No (%) receiving serotonin reuptake inhibitors	No (%) receiving tricyclic antidepressants
Total drop outs (58 studies)	2817 (32.3)	2701 (33.2)
Reason for drop out:		
Side effects (51 studies)	2556 (15.4)	2445 (18.8)
Inefficacy (39 studies)	2155 (7.0)	2042 (6.8)

TABLE III—Odds ratio of drop out in patients treated with serotonin reuptake inhibitors compared with tricyclic and related antidepressants

Drop outs	Odds ratio	95% Confidence interval
Fluoxetine	0.921	0.699 to 1.215
Fluvoxamine	1.013	0.756 to 1.358
Paroxetine	0.973	0.779 to 1.216
All serotonin reuptake inhibitors	0.950	0.816 to 1.107*
Due to side effects	0.805	0.648 to 1.001
Due to inefficacy	1.022	0.801 to 1.304

* $Q=78.79$, $df=57$; $p=0.0295$.

depressants, after up to eight weeks of treatment (mean difference 0.13; 95% confidence interval -1.01 to 1.28) (fig 1). Tricyclic and related antidepressants were significantly more effective than the serotonin reuptake inhibitors in trials using the 17 item scale (mean difference 1.29, 0.28 to 2.30) (fig 1) but the difference was not clinically important.

Overall, in the 20 trials which presented the standard deviation of the Hamilton score the tricyclic and related antidepressants showed a small but non-significant benefit in efficacy when compared with the serotonin reuptake inhibitors (standardised difference 0.004, 95% confidence interval -0.096 to 0.105).

We ascribed weighted average standard deviations to the remaining 33 studies that used the 17 or 21 item Hamilton score as an end point so that the results for all 49 studies could be pooled. A standard deviation of 8.27 was ascribed to studies using the 21 item scale and 6.81 to those using the 17 item scale. Again, there were no differences in trials using either the 21 item scale (mean difference 0.147; -0.597 to 0.891) or the 17 item scale (0.727, 0.083 to 1.370). This strengthens the inference that there is no significant difference in efficacy between serotonin reuptake inhibitors and tricyclic and related drugs.

ACCEPTABILITY TO PATIENTS

Fifty eight studies reported drop out rates during the treatment phase. The pooled drop out rate was 32.3% in patients receiving serotonin reuptake inhibitors and 33.2% among those receiving tricyclic and related antidepressants (table II). The odds ratio for drop out for serotonin reuptake inhibitors compared with tricyclic and related antidepressants was estimated to be 0.95, which was not significantly different from 1 (95% confidence interval 0.816 to 1.107) (table III, fig 2).

Several trials reported the reason given by patients for dropping out from treatment. The two most commonly cited reasons were lack of efficacy and side effects. There was no difference in the drop out rate attributed to lack of efficacy among the two groups but drop out because of side effects was slightly more common among patients taking tricyclic antidepressants (tables II and III).

Discussion

The results of this analysis are particularly important because the populations in the trials were generally similar to that found in primary or ambulatory care, where most first line treatment is undertaken. Our most important finding was that there was no statistically or clinically significant difference in the accept-

FIG 1—Difference (95% confidence interval) in mean Hamilton score in patients treated with serotonin reuptake inhibitors or tricyclic and related antidepressants (from data reported at last week of trial)

ability of serotonin reuptake inhibitors and tricyclic and related antidepressants in patients with major depression.

The serotonin reuptake inhibitors seem to have similar efficacy to the tricyclic and related antidepressants, but the analysis of efficacy is less reliable than that of acceptability because intention to treat analyses were not widely used, different Hamilton scales were

used, and reporting of standard deviation was inadequate. The length of follow up in all the studies (median six weeks) was short relative to the generally accepted desirable duration of treatment in this population.⁸⁰

In addition the study populations were heterogeneous despite all meeting the criteria for major depression. Some patients had a short lived mood disorder, which would be likely to resolve rapidly, perhaps without treatment. Others had a more persistent disorder, some of whom had already been treated unsuccessfully. Spontaneous resolution is likely to reduce the ability of any trial to show differences in the effect of treatment. On the other hand, the fact that some patients had already failed to respond to tricyclics before entering the trial might have introduced a bias against this class of drugs.

Better designed studies with more complete reporting of data would enable more reliable estimates of efficacy of treatment. This is essential for the translation of research findings into clinical practice and should be mandatory in reports in clinical journals.

The lack of evidence of greater efficacy and acceptability of serotonin reuptake inhibitors means that their adoption as the drugs of choice in major depression may be premature, although they may have a role in subgroups of patients in whom other treatments are contraindicated or have failed.

The other argument for prescribing serotonin reuptake inhibitors has been their reported lower toxicity in overdose compared with some antidepressants. However, more knowledge of the long term effects of these drugs is needed before they can be recommended as a safe alternative to tricyclic antidepressants, which are less expensive, equally effective, and well tolerated. It may be more effective to adopt alternative strategies for improving mental health and reducing suicides, as outlined in the recommendations of the Defeat Depression campaign of the Royal Colleges of Psychiatrists and General Practitioners.⁸⁰

In conclusion, our meta-analysis of randomised controlled trials indicates that selective serotonin reuptake inhibitors have no significant advantage in efficacy or acceptability over tricyclic and related antidepressants. This is at odds with some of the claims made in the promotion of serotonin reuptake inhibitors and does not support their increasing use as routine first line treatment for major depression.

FIG 2—Odds ratio of drop out in patients treated with selective serotonin reuptake inhibitors and tricyclic and related antidepressants

- 1 Sertraline for treatment of depression. *Medical Letter on Drugs and Therapeutics* 1992;34:47-8.
- 2 Edwards JG. Selective serotonin reuptake inhibitors. *BMJ* 1992;304:1644-6.
- 3 Fradd SO. Selective serotonin reuptake inhibitors. *BMJ* 1992;305:366.
- 4 British Association for Psychopharmacology. *Guidelines for treating depressive illness with antidepressants*. London: British Association for Psychopharmacology, 1992.
- 5 Schmidt MJ, Fuller RW, Wong DT. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. *Br J Psychiatry* 1988; 153(suppl 3):40-6.
- 6 Altamura AC, De Novellis F, Guercetti G, Invernizzi G, Percudani M, Montgomery SA. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. *Int J Clin Pharm Res* 1989;9:391-6.
- 7 Amore M, Bellini M, Berardi D, Berlinazzi G, Cervino A, Cremonini G, et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. *Current Therapeutic Research* 1989;46:815-20.
- 8 Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. *Acta Psychiatr Scand* 1989;80(suppl 350):141-2.
- 9 Bignamini A, Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. *Int Clin Psychopharm* 1992; 6(suppl 4):37-41.
- 10 Bramanti P, Ricci RM, Roncari R, Bilone F, Inga F, Teti V, et al. An Italian multicenter experience with fluvoxamine, a new antidepressant drug, versus imipramine. *Current Therapeutic Research* 1988;43:718-24.
- 11 Brasseur R. A multicentre open trial of fluoxetine in depressed outpatients in Belgium. *Int Clin Psychopharmacol* 1989;4(suppl 1):107-11.
- 12 Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. *J Clin Psychiatry* 1984;45:414-9.
- 13 Bressa GM, Brugnoti R, Pancheri P. A double-blind study of fluoxetine and imipramine in major depression. *Int Clin Psychopharmacol* 1989;4(suppl 1):69-73.
- 14 Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. *J Clin Psychiatry* 1985;46:32-7.
- 15 Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. *J Clin Psychiatry* 1985;46:26-31.

- 16 Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghron JJ, *et al*. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. *J Clin Psychiatry* 1990;51(suppl B):28-33.
- 17 Cohn JB, Crowder JE, Wilcox CS, Ryan PJ. A placebo- and imipramine-controlled study of paroxetine. *Psychopharmacol Bull* 1990;26:185-9.
- 18 Come SJ, Hall JR. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. *Int Clin Psychopharmacol* 1989;4:245-54.
- 19 Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. *J Affective Disord* 1990;18:289-99.
- 20 Debus JR, Rush AJ, Himmel C, Tyler D, Polatin P, Weissenburger J. Fluoxetine versus trazodone in the treatment of outpatients with major depression. *J Clin Psychiatry* 1988;49:422-6.
- 21 De Jonghe F, Swinkels J, Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. *Pharmacopsychiatry* 1991;24:21-7.
- 22 De Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. *Pharmacopsychiatry* 1991;24:62-7.
- 23 De Wild JE, Mertens C, Wakelin JS. Clinical trials of fluvoxamine vs clomipramine with single and three times daily dosing. *Br J Clin Pharmacol* 1983;15(suppl 3):427-31S.
- 24 Dick P, Ferrero E. A double-blind comparative study of the clinical efficacy of fluvoxamine and clomipramine. *Br J Clin Pharmacol* 1983;15:419-25S.
- 25 Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. *J Clin Psychiatry* 1985;46:84-7.
- 26 Dorman T. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. *Int Clin Psychopharmacol* 1992;6(suppl 4):53-8.
- 27 Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, *et al*. A comparison of paroxetine, imipramine and placebo in depressed outpatients. *Br J Psychiatry* 1991;159:394-8.
- 28 Dunner DL, Cohn JB, Walshe T, Cohn CK, Feighner JP, Fieve RR, *et al*. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. *J Clin Psychiatry* 1992;53(suppl 2):57-60.
- 29 Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. *J Clin Psychiatry* 1991;52(suppl 6):62-7.
- 30 Falk WE, Rosenbaum JF, Otto MW, Zuskov PM, Weilburg JB, Nixon RA. Fluoxetine versus trazodone in depressed geriatric patients. *J Geriatr Psychiatry Neurol* 1989;2:208-14.
- 31 Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, *et al*. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. *J Clin Psychiatry* 1991;52:329-35.
- 32 Feighner JP, Boyer WF, Meredith CH, Hendrickson GG. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. *Int Clin Psychopharmacol* 1989;4:239-44.
- 33 Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. *J Clin Psychiatry* 1985;46:20-5.
- 34 Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. *J Clin Psychiatry* 1985;46:369-72.
- 35 Ferreri M. Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. *Int Clin Psychopharmacol* 1989;4(suppl 1):97-101.
- 36 Ginestet D. Fluoxetine in endogenous depression and melancholia versus clomipramine. *Int Clin Psychopharmacol* 1989;4(suppl 1):37-40.
- 37 Gonella G, Bagnoli G, Ecarl U. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. *Curr Med Res Opin* 1990;12:177-84.
- 38 Guelfi JD, Dreyfus JF, Pichot P, and the GEPECEP. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. *Br J Clin Pharmacol* 1983;15(suppl 3):411-7S.
- 39 Guillebert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, *et al*. A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients. *Acta Psychiatr Scand* 1989;80(suppl 350):132-4.
- 40 Guy W, Wilson WH, Ban TA, King DL, Manov G, Fjotland OK. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. *Psychopharmacol Bull* 1984;20:73-8.
- 41 Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. *Int Clin Psychopharmacol* 1992;6(suppl 4):43-51.
- 42 Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST. A double-blind placebo-controlled study of fluvoxamine and imipramine in outpatients with primary depression. *Br J Clin Pharmacol* 1983;15(suppl 3):433-8S.
- 43 Kuhs H, Rudolf GAE. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. *Acta Psychiatr Scand* 1989;80(suppl 350):145-6.
- 44 Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. *Br J Psychiatry* 1988;153(suppl 3):64-8.
- 45 Lapiere YD, Browne M, Horn E, Oyewumi LK, Sarantidis D, Roberts N, *et al*. Treatment of major effective disorder with fluvoxamine. *J Clin Psychiatry* 1987;48:65-8.
- 46 Laursen AL, Mikkelsen PL, Rasmussen S, le Fèvre Honoré P. Paroxetine in the treatment of depression—a randomized comparison with amitriptyline. *Acta Psychiatr Scand* 1985;71:249-55.
- 47 Levine S, Deo R, Mahardevan K. A comparative trial of a new antidepressant, fluoxetine. *Br J Psychiatry* 1987;150:653-5.
- 48 Loeb C, Albano C, Gandolfo C. Fluoxetine versus imipramine. *Int Clin Psychopharmacol* 1989;4(suppl 1):75-9.
- 49 Manna V, Martucci N, Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. *Int Clin Psychopharmacol* 1989;4(suppl 1):81-8.
- 50 March JS, Kobak KA, Jefferson JW, Mazza J, Greist JH. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. *J Clin Psychiatry* 1990;51:200-2.
- 51 Mertens C, Pintens H. Paroxetine in the treatment of depression. A double blind multicentre study versus mianserin. *Acta Psychiatr Scand* 1988;77:683-8.
- 52 Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. *Acta Psychiatr Scand* 1988;78:384-90.
- 53 Mullin JM, Pandita-Gunawardena VR, Whitehead AM. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. *Br J Clin Pract* 1988;42:51-5.
- 54 Nielsen OA, Morsing I, Petersen JS, Larsen T, Møller SE, Manniche PM, *et al*. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. *Acta Psychiatr Scand* 1991;84:233-41.
- 55 Norton KRW, Sireling LJ, Bhat AV, Rao B, Paykel ES. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. *J Affective Disord* 1984;7:297-308.
- 56 Perez A, Ashford JJ. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. *Curr Med Res Opin* 1990;12:234-41.
- 57 Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. *J Clin Psychiatry* 1989;50:290-4.
- 58 Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HCL: A. data from a 6-week double-blind parallel design trial vs. imipramine and placebo. *Psychopharmacol Bull* 1989;25:267-71.
- 59 Phanjo A, Wonnacott S, Hodgson A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. *Acta Psychiatr Scand* 1991;83:476-9.
- 60 Poelinger W, Haber H. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. *Int Clin Psychopharmacol* 1989;4(suppl 1):47-50.
- 61 Rahman MK, Akhtar MJ, Savla NC, Sharma RR, Kellett JM, Ashford JJ. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. *Br J Clin Pract* 1991;45:255-8.
- 62 Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, Lapiere YD, *et al*. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. *J Clin Psychiatry* 1990;51(suppl B):18-27.
- 63 Ropert R. Fluoxetine versus clomipramine in major depressive disorders. *Int Clin Psychopharmacol* 1989;4(suppl 1):89-95.
- 64 Roth D, Mattes J, Sheehan KH, Sheehan DV. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. *Prog Neuropsychopharmacol Biol Psychiatry* 1990;14:929-39.
- 65 South Wales Antidepressant Drug Trial Group. A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. *Int Clin Psychopharmacol* 1988;3:75-81.
- 66 Stark P, Hardison D. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. *J Clin Psychiatry* 1985;46:53-8.
- 67 Tamminen TTA, Lehtinen VV. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. *Int Clin Psychopharmacol* 1989;4(suppl 1):51-6.
- 68 Taneri Z, Köhler R. Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder. *Int Clin Psychopharmacol* 1989;4(suppl 1):57-61.
- 69 Young JPR, Coleman A, Lader MH. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. *Br J Psychiatry* 1987;151:337-40.
- 70 Leizorovicz A, Haugh MC, Boissel JP. Meta-analysis and multiple publication of clinical reports. *Lancet* 1992;340:1102-3.
- 71 Hamilton M. A rating scale for depression. *J Neurol, Neurosurg Psychiatry* 1960;23:56-62.
- 72 Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 1967;6:278-96.
- 73 Mann A, Murray R. Measurement in psychiatry. In: Hill P, Murray R, Thorley A, eds. *Essentials in postgraduate medicine*. 2nd ed. London: Academic Press, 1987.
- 74 Cochran WG. The combination of estimates from different experiments. *Biometrics* 1954;10:101-29.
- 75 Der Simonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clin Trials* 1986;7:177-88.
- 76 Peto R. Why do we need systematic overviews of randomised trials? *Stat Med* 1987;6:223-40.
- 77 Long AF, Sheldon TA. Enhancing effective and acceptable purchaser and provider decisions: overview and methods. *Quality in Health Care* 1992;1:74-6.
- 78 Lader M. Fluoxetine efficacy vs comparative drugs: an overview. *Br J Psychiatry* 1988;153(suppl 3):51-8.
- 79 Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. *Stat Med* 1989;8:141-51.
- 80 Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. *BMJ* 1992;305:1198-202.

(Accepted 23 February 1993)